Hubei Goto Biopharm Co.,Ltd. (SHE:300966)

Hubei Goto Biopharm Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	549.56	532.57	565.5	604.4	588.37	464.71
Other Revenue	4.03	4.03	0.9	0.17	2.52	3.41
Revenue	553.58	536.6	566.4	604.57	590.89	468.12
Revenue Growth (YoY)	-2.74%	-5.26%	-6.31%	2.32%	26.23%	0.71%
Cost of Revenue	445.31	435.71	450.29	466.77	446.63	362.21
Gross Profit	108.28	100.89	116.11	137.81	144.26	105.9
Selling, General & Admin	68.33	67.29	50.16	42.5	40.58	19.69
Research & Development	55.47	51.08	38.1	45.15	37.12	21.6
Other Operating Expenses	-7.93	-6.98	-3.53	-0.17	1.53	1.78
Operating Expenses	122.13	115.62	89.17	92.35	79.78	44.51
Operating Income	-13.85	-14.73	26.93	45.46	64.48	61.39
Interest Expense	-30.46	-23.52	-13.18	-13.68	-5.17	-6.75
Interest & Investment Income	0.77	1.05	2.39	1.92	1.19	0.64
Currency Exchange Gain (Loss)	1.12	1.12	1.05	2.24	-0.6	-0.83
Other Non Operating Income (Expenses)	-1.67	-1.41	-0.5	-0.59	-0.72	-0.24
EBT Excluding Unusual Items	-44.09	-37.48	16.7	35.35	59.17	54.21
Gain (Loss) on Sale of Investments	-0.51	-0.35	-0.01	-0.18	-1.05	-0.25
Gain (Loss) on Sale of Assets	-1.46	0.11	0.17	-0.01	-	-0.01
Asset Writedown	-10.04	-10.46	-2.23	-0.96	-0.06	-0.5
Legal Settlements	-	-	-0.03	-0.05	0.01	-0.02
Other Unusual Items	4.25	2.64	4.53	4.36	28.05	6.8
Pretax Income	-51.85	-45.54	19.12	38.51	86.12	60.24
Income Tax Expense	-16.54	-13.88	-2.17	-1	8.05	7.05
Earnings From Continuing Operations	-35.31	-31.66	21.29	39.51	78.07	53.2
Minority Interest in Earnings	5.26	4.07	1.72	0.69	0.26	0.09
Net Income	-30.06	-27.59	23.01	40.21	78.33	53.29
Net Income to Common	-30.06	-27.59	23.01	40.21	78.33	53.29
Net Income Growth	-	-	-42.78%	-48.67%	46.99%	-27.00%
Shares Outstanding (Basic)	112	115	115	115	106	86
Shares Outstanding (Diluted)	112	115	115	115	106	86
Shares Change (YoY)	1.26%	-0.05%	0.13%	8.77%	22.87%	0.08%
EPS (Basic)	-0.27	-0.24	0.20	0.35	0.74	0.62
EPS (Diluted)	-0.27	-0.24	0.20	0.35	0.74	0.62
EPS Growth	-	-	-42.86%	-52.81%	19.63%	-27.06%
Free Cash Flow	-360.78	-332.2	-341.12	-431.98	-32.91	-5.09
Free Cash Flow Per Share	-3.21	-2.89	-2.97	-3.76	-0.31	-0.06
Dividend Per Share	-	-	0.016	-	0.136	-
Gross Margin	19.56%	18.80%	20.50%	22.79%	24.41%	22.62%
Operating Margin	-2.50%	-2.74%	4.75%	7.52%	10.91%	13.11%
Profit Margin	-5.43%	-5.14%	4.06%	6.65%	13.26%	11.38%
Free Cash Flow Margin	-65.17%	-61.91%	-60.23%	-71.45%	-5.57%	-1.09%
EBITDA	33.26	28.26	53.4	69.76	86.76	82.58
EBITDA Margin	6.01%	5.27%	9.43%	11.54%	14.68%	17.64%
D&A For EBITDA	47.11	42.98	26.47	24.3	22.28	21.18
EBIT	-13.85	-14.73	26.93	45.46	64.48	61.39
EBIT Margin	-2.50%	-2.74%	4.75%	7.52%	10.91%	13.11%
Effective Tax Rate	-	-	-	-	9.35%	11.70%
Revenue as Reported	553.58	536.6	566.4	604.57	590.89	468.12

Source: S&P Global Market Intelligence. Standard template. Financial Sources.